Cost and Compliance Dominate Agenda for 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cost and Compliance Dominate Agenda for 2011
Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 26-32

In addition to the threat of jail time, prosecutors also are looking to ban companies committing fraud from doing business with Medicare and Medicaid. The HHS inspector-general issued guidelines in October 2010 that signal more aggressive pursuit of exclusion penalties against executives who should or could have known of illegal behavior. Last year, KV Pharmaceutical (Bridgeton, MO) had to sever ties with its CEO when he was hit by an exclusion order that would have halted company sales to federal agencies.

KV is one of several leading pharmaceutical companies embroiled in drug manufacturing and quality control issues that have drawn the scrutiny of FDA and Congress. Johnson & Johnson (J&J, New Brunswick, NJ) made front-page news throughout 2010 with multiple recalls of McNeil Consumer Healthcare's over-the-counter painkillers and cold medicines. Pfizer and J&J also had to recall thousands of drug packages tainted by foul odors that evidently came from chemicals applied to shipping pallets used in Puerto Rican plants. Glass flakes have been found in intravenous drugs made by Amgen (Thousand Oaks, CA) and Novartis.

FDA wants to conduct more inspections of foreign plants and to move aggressively against manufacturers found in violation of the rules. In addition to waving the enforcement stick, agency leaders talk of more guidance and assistance to help companies meet quality and safety standards and to bring high quality drugs more quickly to patients. The challenge is for industry and regulators to find the resources and appropriate policies to achieve these objectives in the coming year.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here